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Abstract 
To determine the HCV genotypes among HCV-infected patients in 
Sulaimani governorate Kurdistan region- Iraq, 76 blood samples were 
collected (60 samples were positive and 16 samples were negative for anti-
HCV antibody) from different groups  the samples comprised: 21 (27.63%) 
hemodialysis patients, 38 (50%) thalassemia patients, 4 (5.26%) cancer 
patients, 3 (3.95%) gastritis patients, 1 (1.32%) hemophilia patient and 9 
(11.84%) blood donors. RT- nested PCR analysis showed that 35 (46.05%) 
were positive and 41 (53.95%) were negative for HCV-RNA. Amplification 
of 5’UTR of HCV-RNA positive samples were done by RT- nested PCR; the 
amplified product was purified and sequenced in IBL laboratory in Vienna. 
The sequenced samples were BLAST on NCBI online website. The 
alignment sequence and phylogenetic analysis used CLUSTAL W online 
software version 1.83 of 24 samples showed that genotype 1 was the 
predominant genotype among HCV infected patients in Sulaimani 
governorate, with an overall of (87.5%) patients. Genotype 2 was found in 
(8.3%), and genotype 4 was seen in (4.2%) patients. 
The study aimed to detect the HCV- RNA in the blood samples by RT- 
nested PCR analysis and sequencing in order to determine the HCV 
genotypes in Sulaimani governorate-Kurdistan-Iraq. 
 
Keyewords: HCV genotyping, HCV geographycial distribution, HCV PCR- 
sequencing 
 
Introduction 
The hepatitis C virus (HCV) is the main causative pathogen of post-
transfusion hepatitis (Gallego and Varani, 2002). The virus establishes a 
persistent infection in the liver, leading to the development of chronic 
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hepatitis, liver cirrhosis and hepatocellular carcinomas (Yokota et al., 2003). 
More than 75% of HCV infections become chronic and up to 20–30% 
progress to cirrhosis (Ardalan et al., 2004).  According to the estimations of 
the World Health Organization, approximately 170 million people, 3% of the 
world population, are HCV positive with 3 to 4 million de novo infections 
each year (Pan et al., 2007). HCV, first identified in 1989 (Choo et al., 
1989), is an enveloped virus classified in the Hepacivirus genus of the family 
Flaviviridae (Lindenbach et al., 2007). HCV has a single-stranded, positive-
sense RNA genome which contains two short untranslated region at each end 
(5’UTR and 3’UTR) and a single open reading frame that is translated to 
yield the viral proteins in the form of a polyprotein (Carrat et al., 2004). 
HCV demonstrates a high degree of sequence variation throughout its 
genome (Zein, 2000). Based mainly on phylogenetic analyses, all HCV 
isolates are grouped into six major HCV genotypes comprising numerous, 
more closely related subtypes (Robertson et al., 1998). Knowledge about 
HCV genotypes that infects people is important and affects the dosage and 
duration of the antiviral therapy. Patients infected with genotype 2 or 3 
showed better response than those infected with genotype 1 or 4 (Carrat et 
al.,2004). 
 
Materials and Methods  
Sampling. Blood samples were collected between July/2009-
October/2009 in Sulaimani governorate-Kurdistan-Iraq. Seventy six blood 
samples were collected from different groups all samples were screened for 
anti-HCV antibody by enzyme linked immunosorbent assay (ELISA) 
technique. The samples were collected from different ages, ranging from (2 -
80) year old. The serum was directly separated and each specimen was 
divided into two aliquot in labeled screw caped vials and frozen at (– 40◦C) 
until used for performing the tests: one for HCV RNA detection and the 
other for sequencing.  
 
HCV RNA detection and RT-PCR.  
HCV RNA extracted from anti-HCV positive and anti-HCV negative 
sera. Five μl of extracted RNA was put in 95◦C for 1 minute then placed on 
ice, single step cDNA synthesis and first round PCR was done according to 
the STRPTm Hepatitis C Virus detection kit- Cinnagen.  
Three μl from the first round PCR product (RT-PCR) was used for 
the second round PCR (nested PCR) which gives (216 bp) product, the 
mixture put in thermal cycler run 35 cycles with the following parameters: 
93◦C – 40 seconds, 60◦C – 40 seconds, 72◦C – 40 seconds. The PCR products 
were analyzed on 2% agarose gel.  
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Amplification of HCV 5’UTR by RT nested PCR.  
cDNA was synthesized at 45◦C – 60 minute using 1μl of outer anti-
sense primer according to RevertAidTm First Strand cDNA Synthesis kit- 
Fermantas. First round PCR reaction was performed in a volume of 25μl. By 
using outer sense (5’-CGTTAGTATGAGTGTCGTGC-3’) and outer anti-
sense (5’-GGTGCACGGTCTACGAGACCT-3’) primers. The samples were 
placed in a thermal cycler. The samples were preheated at 94˚C for 3 minute 
followed by 35 cycles, each consisting of denaturing for 30 seconds at 94˚C, 
annealing for 40 seconds at 59.4˚C, and extension for 30 seconds at 72˚C 
with the final elongation at 72˚C for 10 minutes. For the amplification of 
341bp 5’UTR nested PCR was analyzed using inner sense (5’-
AGTGTCGTGCAGCCTCCAGG-3’) and inner anti-sense (5’-
GCAAGCACCCTATCAGGCAGT-3’) primers. The samples were 
preheated at 94˚C for 3 minutes followed by 35 cycles, each consisting of 
denaturing for 30 seconds at 94˚C, annealing for 40 seconds at 61.5˚C, and 
extension for 30 seconds at 72˚C with the final elongation at 72˚C for 10 
minutes. 
 
Sequencing PCR of 5’UTR and phylogenetic analysis.  
The amplified product was purified and sequenced in IBL laboratory 
in Vienna. The sequenced samples were BLAST on NCBI online website. 
The alignment sequence and phylogenetic analysis used CLUSTAL W 
online software version 1.83. The accession numbers of the prototype 
genotype sequences used to compare the 5’UTR sequences were as follows: 
genotype 1, AJ006322, EU164941, EU256033, EU862829, AF009606, 
AF011751, M62321, D10749. genotype 2, AB030907, AF177036. genotype 
3, D17763. genotype 4, Y11604, AY766601. genotype 5, Y13184. genotype 
6, D84262.  
Statistical analysis. Statistical analysis was performed using free 
SPSS version 16 software, by applying the statistical analysis (Chi-square) 
test. P value less than 0.05 was considered as statistically significant.  
 
Results.  
The results of screening the 76 blood RT-PCR analysis showed that 
35 (46.05%) samples were positive and 41 (53.95%) were negative for HCV-
RNA, and statistical analysis showed significant differences between both 
techniques (Table 1). Two hundred and sixteen (216)bp band of the positive 
control was used as a detector for the HCV-RNA. The gel electrophoresis 
analysis, represent RT- nested PCR products for detected HCV in gastritis, 
hemophilia and cancer samples were clarified in (Fig.1). On the basis of 
sequencing and phylogenetic analysis, the 24 Sulaimani samples were 
classified as follows: genotype 1 in 21 patients (87.5%), genotype 2 in 2 
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patients (8.3%) and one patient with genotype 4 (4.2%) (Table 2). 
Phylogenetic tree of 24 Sulaimani HCV samples and some close reference 
HCV strains published in Gene Bank by using CLUSTAL W online software 
as shown in (Fig. 2).  
Table 1: Positive and negative results for both ELISA and RT-PCR 
Group Total No. 
Examined 
ELISA RT-PCR 
positive negative positive negative 
Thalassemia 38 34 4 14 24 
Hemodialysis 21 16 5 11 10 
Cancer 4 4 0 4 0 
Gastritis 3 3 0 2 1 
Hemophilia 1 1 0 1 0 
Blood donor 9 2 7 3 6 
Total 76 60 (78.95) % 16 (21.05 ) % 35 (46.05) % 41 (53.95)  % 
P value 0.002 
Figure 1: Gel electrophoresis for RT-nested PCR product from patients with gastritis, 
hemophilia and cancer samples 
M: 50bp DNA ladder, NC: negative control, PC: positive control, samples 1- 8: represent 
samples 
Table 2: The number and percentage of HCV genotypes in different patient groups in 
Sulaimani governorate 
No. of samples  assigned to the following genotypes Sequenced 
No. 
Group 
 Genotype 1         Genotype 2             Genotype 4 
 
8 (33.3%)                   8                                   0                              0 
 
8 (33.3%)                   7                                   1                              0 
 
4(16.7%)                    3                                   1                              0 
 
1 (4.2%)                     1                                   0                              0 
 
1 (4.2%)                     0                                   0                              1 
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Hemodialysis 
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Figure 2: phylogenetic tree of HCV 5’UTR of 24 Sulaimani HCV samples with 
reference HCV strains published in Gene Bank.  S: represent Sulaimani HCV samples. 
2 (8.3%)                     2                                   0                              0 
 
24                            21 (87.5%)                  2 (8.3%)                 1 (4.2%) 
 
Blood donor 
Total 
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Discussion  
The ultimate goal of this investigation is to determine the genotype of 
HCV in Sulaimani governorate. The importance was to provide treatment of 
HCV patients. This study is considered to be the first study on the 
genotyping of HCV in Sulaimani governorate, Kurdistan region of Iraq 
among different patient groups. A total of 76 serum samples were 
investigated for HCV- RNA, followed by genotyping, out of those, 35 
(46.05%) sera displayed HCV-RNA positive results and 41 (53.95%) sera 
demonstrated negative HCV-RNA (Table 1). The results were in agreement 
with those obtained by Hama, (2009) who observed that not all anti-HCV 
positive samples showed positive results for HCV-RNA (63.7%) in 
Sulaimani. Two (12.50%) of the 16 negative anti-HCV samples displayed 
HCV-RNA positive results. The obtained results were relatively in 
agreement with the results of Al- Kubaisy et al., (2006)  who found that 2 
(16.7%) samples were positive for HCV-RNA from 12 anti-HCV negative 
sera. The presence of specific antibodies against HCV and absence of HCV-
RNA is a common finding and may be related to one of the following causes: 
a) there is a cross reaction with antibodies different from anti-HCV (Ren et 
al., 2005),  b) the initial level of viraemia may be low and below detectable 
levels for PCR assay at the time of sampling (Kanistanon et al., 1997; Mison 
et al., 1997), or c) patients might have been cured of HCV infection at the 
time of sampling (Simmonds, 1997). HCV has high genomic variability and 
at least six different genotypes and an increasing number of subtypes have 
been reported (Simmonds, 1999). Genotypes 1, 2 and 3 are predominantly 
found in Europe, Japan, Brazil, Australia and the United States (Busek and 
Oliveria, 2003). HCV genotyping is important because it provides 
information as to strain variation and potential association with disease 
severity. In addition, it is of epidemiologic value because it sheds light on 
whether prevalent HCV strains are similar to that endemic in a certain 
region, such as here in the Middle East (Kabir et al., 2006). Although, the 
5'UTR contains multiple  genotype-specific sequences distributed over small 
variable regions, which provide accurate genotyping information for HCV 
genotypes but is not able to completely differentiate between all subtypes 
(Chen and Weck, 2002; Noppornpanth et al., 2006). In the present study the 
HCV genotypes were determined by sequencing the 5’UTR and comparing it 
with reference sequences of known genotypes. A similar assay was used for 
HCV genotyping by Campiotto et al., (2005), and Idrees et al., (2009). 
Results of the sequence analysis of 5’UTR region demonstrated that 
genotype 1, 2 and 4 were detected in 21 (87.5%), 2 (8.3%), and 1 (4.2%) 
samples respectively as shown in (Table 2). Genotype 1 was found as a 
predominant genotype among studied patients in Sulaimani governorate. 
These results were in accordance with the predominance of genotype 1 
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observed in most countries worldwide (Viazov et al., 1994; Simmonds, 
1995). Genotype 1 representing 77% in China, 82% in Spain, 90% in Brazil 
(Holland et al., 1996), 86.92% in Germany (Feucht et al., 1996), 85% in the 
United States (O’Brien et al., 1997), and 82% in Bulgarian patients 
(Anotonov, 2010). Genotype 1 was the predominated in Turkey and Israel as 
well (Chamberlain et al., 1997; Bozdayi et al., 2004), and based on a study 
done in Jordan, genotype 1 was the dominant genotype (73.3%) (Bdour, 
2002). The pattern of observed genotypes  are similar to those  reported  by 
Jia-Qing et al., (2006) from Hong Kong  but  it was different from other 
Middle East countries such as Republic of Yemen, Kuwait, Iraq, and Saudi 
Arabia, where genotype 4 was the most prevalent (Ohno et al., 1996). 
Although genotype 4 was almost entirely reported from the Middle East and 
western countries (Mellor et al., 1995), this genotype was uncommon in 
Sulaimani governorate according to the results of this study. Data from the 
present work differ from those published by Al-Kubaisy et al., (2006) who 
observed that HCV genotype 4 (35.4%) was more predominant than other 
genotypes among Iraqi thalassemia patients, also differ from the results of 
Al- Kubaisy, (1998) who demonstrated that the common HCV- genotypes 
circulating among Iraqi pregnant women were 4, 1, 1a, 1b and 3a, in 
decreasing order. As mentioned, the present study indicated that in Sulaimani 
governorate, HCV genotype 1 was predominant. This result was not 
surprising because Kabir et al., (2006) and Somi et al., (2008) demonstrated 
that HCV genotype 1 was the most prevalent genotype in Iran, a neighboring 
country to the governorate. This can be attributed to the fact that many 
patients get treatment in the Iranian hospitals, familiar relationships, also due 
to the mass-fled and the immigration between the province and Iran, and 
afterwards the return of many inhabitants of Sulaimani who lived in Iran for 
along time. Another important finding in this study was the detection of 
genotype 2 for the first time in Iraq from two patients one of them coming 
back from Europe. This genotype was found in many countries like, Spain 
(Esteban et al., 1996), Japan (Lee et al., 2001; Mukaide et al., 2005), Italy 
(Cicciarello et al., 1997;Simpore et al., 2004), Brazil (Campiotto et al., 
2005), and Mexico (Sosa-Jurado et al., 2010). The presence of this genotype 
in Sulaimani governorate may reflect the growing communications with 
these countries. Another important finding in the present study was the 
detection of genotype 4 only in one hemophilic patient who had a history of 
treatment in Baghdad. This result was in a concordance with the results of 
Al-Kubaisy, (1998) and Al-Kubaisy et al., (2006) they reported predominate 
of genotype 4 among pregnant women and thalassemia patients in Iraq 
respectively. Besides, in a study, the predominance of HCV genotype 4 is 
reported in the Arab world, and most other countries in the Middle East 
(Matar et al., 1996). It is also worth mentioning that genotype 4 was the 
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second major genotype existing in Iran (Idrees et al., 2009). Multiple 
sequence alignment of Sulaimani HCV samples with genotype prototype 
sequences selected from the Gene Bank (Fig 2) the 24 Sulaimani HCV 
samples can be classified on the basis of phylogenetic analysis of the 5’UTR, 
with reference isolates and Sulaimani HCV samples grouped according to 
the close relatedness to reference genotype isolates. The occurrence of many 
variants is not surprising because such variations have also been reported 
from neighboring countries. The possibility of identifying more and more 
variants cannot be ruled out in the present situation of high prevalence of 
hepatitis C in Iraq. In the present study, the HCV viral samples didn’t 
classify to subtype level due to the limitations of information on 
differentiation between different HCV subtypes by 5’UTR analysis. In some 
isolates, only one or two minor nucleotide changes distinguish subtypes, e.g., 
an adenine to guanine substitution between subtypes 1a and 1b. The relative 
failure in subtyping the genotype 2 samples at the 5’UTR by LiPA 
methodology has already been reported (Stuyver et al., 1995). Furthermore 
this method was unable to detect more than one genotype if present in the 
patient (Idrees et al., 2009). Nevertheless, classifying HCV at the genotype 
level has been shown to be sufficient for clinical prognosis and treatment 
orientation (Campiotto et al., 2005).  
 
Conclusion 
We conclude that (i) The 5'UTR sequence analysis was sufficient for 
the routine genotyping of HCV in clinical settings. (i i) The predominant 
HCV genotype circulating among HCV- infected patients in Sulaimani 
governorate, Kurdistan region of Iraq was genotype 1.  
 
References: 
Gallego J; and Varani G. 2002. The hepatitis C virus internal ribosome-entry 
site: a new target for antiviral research. Biochemical Society Transactions; 
30 (part 2):140-146.  
Yokota T; Sakamoto N; Enomoto N; Tanabe Y; Miyagishi M; Maekawa S; 
Yi L; Kurosaki M; Taira K; Watanabe M; and Mizusawa H. 2003. Inhibition 
of intracellular hepatitis C virus replication by synthetic and vector-derived 
small interfering RNAs. EMBO reports; 4: 602–608.  
Zein N. N. 2000. Clinical Significance of Hepatitis C Virus Genotypes. Clin 
Microbiol Rev; 13(2): 223-235. 
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; 
Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Ceron D; Degott C; 
Cacoub P; Perronne C; ANRS HCO2 RIBAVIC Study Team. 2004. 
Pegylated interferon alfa-2b vs standard interferon alfa-2b plus ribavirin for 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
385 
chronic hepatitis C in HIV-infected patients: a randomized controlled trial. 
JAMA; 292(23): 2839-2848. 
Ardalan F. A; Osquei M. RF; Toosi M. N; and Irvanloo G. 2004. Synergic 
effect of chronic hepatitis C infection and beta thalassemia major with 
marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional 
study. BMC Gastroenterology; 4: 1- 4. 
Choo Q. L; Kuo G; Weiner A. J; Overby L. R; Bradley D. W; and Houghton 
M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A non-
B viral hepatitis genome. Science; 244(4902): 359-362. 
Lindenbach B. D; Thiel H. J; and Rice C. M. 2007. Flaviviridae: the virus 
and their replication . Fields Virology. eds Knipe DM. and Howley PM. 
(Lippincott Williams & Wilkins Philadelphia) 5th Ed 1: pp.1101-1152.  
Pan Q. W; Henry S. D; Scholte B. J; Tilanus H. W; Janssen H. LA; and van 
der Laan L. JW. 2007. New therapeutic opportunities for Hepatitis C based 
on small RNA. World J Gastroenterol; 13(33): 4431-4436. 
Robertson B; Myers G; Howard C; Brettin T; Bukh J; Gaschen B; Gojobori 
T; Maertens G; Mizokami M; Nainan O; Netesov S; Nishioka K; Shin-I T; 
Simmonds P; Smith D; Stuyver L; and Weiner A. 1998. Classification 
nomenclature and database development for hepatitis C virus (HCV) and 
related viruses: proposals for standardization.  VDN; 143(12): 2493-2503. 
Al-Kubaisy W. A; Al-Naiband K. T; and Habib M. 2006. Seroprevalence of 
hepatitis  C virus specific antibodies among Iraqi children with thalassaemia. 
Eastern Mediterranean Health Journal; 12: 204-210.   
Hama S. A. 2009. Prevalence of Hepatitis B C and D infections among 
Different Risk Groups in Sulaimani Governorate.  Ph.D. Thesis. University 
of Sulaimani.  
Kanistanon D; Neelamek M; Dharakul T; and Songsivilai S. 1997. 
Genotypic Distribution of Hepatitis C Virus in Different Regions of 
Thailand. Journal of Clinical Microbiology; 35(7): 1772–1776.  
Mison L. M; Yong I. F; ODonghue M; Cowley N; Thorlton N; and Hyland 
C. A. 1997. Prevalence of hepatitis C virus and genotype distribution in an 
Australian volunteer blood donor population. Transfusion; 37(1): 73–78. 
Ren F. R; Lv Q. S; Zhuang H; Li J. J; Gong X. Y; Gao G. J; Liu C. L; Wang  
J. X; Yao F. Z; Zheng Y. R; Zhu F; Tiemuer M; Bai X; and Shan H. 2005. 
Significance of the signal-to-cutoff ratios of antihepatitis C virus enzyme 
immunoassays in screening of Chinese blood donors. Transfusion; 45(11): 
1816-1822. 
Simmonds P. 1997. Clinical prevalence of hepatitis C virus genotypes. Gut; 
40: 291–293. 
Simmonds P. 1999. Viral heterogeneity of the hepatitis C virus. J Hepatol; 
31(suppl 1): 54–60. 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
386 
Busek S; and Oliveria G. 2003. Molecular epidemiology of the hepatitis C 
virus in Brazil. Genet Mol Res; 2: 117-23. 
Kabir A; Alavian S-M; and Keyvani H. 2006. Distribution of hepatitis C 
virus genotypes in patients infected by different sources and its correlation 
with clinical and virological parameters: a preliminary study. Comparative 
Hepatology; 5(4): 1-6. 
Chen Z; and Weck K. E. 2002. Hepatitis C virus genotyping: interrogation 
of the 5' untranslated region cannot accurately distinguish genotypes 1a and 
1b. J Clin Microbiol ; 40: 3127-3134. 
Noppornpanth S; Sablon E; De Nys K; Lien T. X; Brouwer J; Brussel M. V; 
Smits S. L; Poovorawan Y; Osterhaus A. D; and Haagmans B. L. 2006. 
Genotyping hepatitis C viruses from Southeast Asia by a novel line probe 
assay that simultaneously detects core and 5' untranslated regions. J Clin 
Microbiol; 44(11): 3969-3974. 
Campiotto S; Pinho J. R. R; Carrilho F. J; Da Silva L. C; Souto F. J. D; 
Spinelli V; Pereira L. M. M. B; Coelho H. S. M; Silva A. O; Fonseca J. C; 
Rosa H; Lacet C. M. C; and Bernardini A. P. 2005. Geographic distribution 
of hepatitis C virus genotypes in Brazil. Brazilian Journal of Medical and 
Biological Research; 38: 41-49. 
Idrees M; Butt. S; Awan Z; Aftab M; Khubaib B; Rehman I; Akram M; 
Manzoor S; Akbar H; Rafiqe S; and Riazuddin S. 2009. Nucleotide identity 
and variability among different Pakistani hepatitis C virus isolates. Virology 
Journal; 6(130): 1-6. 
Anotonov A. K. 2010. Diagnostic and treatment of chronic HCV infection 
in Bulgaia past and present.  Clujul Medical; 1: 13-15. 
Feucht H. H; Zollner B; Schroter M; Hoyer A; Sterneck M; and Polywka S. 
1996. Distribution of Genotypes and Response to Alpha-Interferon in 
Patients with Hepatitis C Virus Infection in Germany. Eur. J. Clin. 
Microbiol. Dis; 15(2): 128-132. 
Holland P. V; Barrera J. M; Ercilla M. J; Yoshiga C. F. T; Wang Y; Deolim 
G. A. B; Betlach B; Kuramoto K; and Okamoto H. 1996. Genotyping 
hepatitis C virus isolates from Spain Brazil China and Macau by a 
simplified PCR method. J. Clin. Microbiol; 34(10): 2372-2378. 
Simmonds P. 1995. Variability of hepatitis C virus. Hepatology; 21(2): 570-
583. 
O’Brien C. B; Henzel B. S; Wolfe L; Gutekunst K; and Moonka D. 1997. 
cDNA sequencing  of the 5’ non coding region (5’NCR) to determine 
hepatitis C genotypes in patients with chronic hepatitis C. Dig. Dis. Sci; 
42(5): 1087-1093.  
Viazov S; Zibert A; Ramakrishnan K; Widell A; Cavicchini A; Schreier E; 
and Roggendorf M. 1994. Typing of hepatitis C virus isolates by DNA 
enzyme immunoassay. Virol Methods; 48(1): 81-91. 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
387 
Bdour S. 2002. Hepatitis C virus infection in Jordanian hemodialysis units: 
serological diagnosis and genotyping. J Med Microbiol; 51: 200-4. 
Bozdayi A. M; Aslan N; Bozdayi G; Turkyilmaz A. R; Sengezer T; Wend U; 
Erkan O; Aydemir F; Zakirhodjaev S; Orucov S; Bozkaya H; Gerlich W; 
Karayalcin S; Yurdaym C; and Uzunalimoglu O. 2004. Molecular 
epidemiology of hepatitis B C and D viruses in Turkish patients. Arch Virol ; 
149: 2115-2129. 
Chamberlain R; Adams N; Saeed A; Simmonds P; and Elliot R. 
1997.Complete nucleotide sequence of a type 4 hepatitis C virus variant: 
The predominant genotype in the Middle East. J Gen Virol; 78: 1341-7. 
Jia-Qing H; Ge Fan Z; Ching L; Man Fung Y; and Benjamin C. Y. 2006. 
Hepatitis B or Hepatitis C Viral Infection and Genotypes –Which Subgroup 
Is More Prone To The Development Of Hepatocellular Carcinoma? A 
Systematic Review. Health and Health Services Research Fund Final Report 
01030421. p.1-33. 
Mellor J; Holmes E. C; Jarvis L. M; Yap P. L; Simmonds P; and The 
International HCV Collaborative Study Group. 1995. Investigation of the 
pattern of hepatitis C virus sequence diversity in different geographical 
regions: Implications for virus classification. J Gen Virol; 76(10): 2493- 
2507. 
Ohno T; Mizokami M; Saleh M. G; Orito E; Ohba K. I; Wu R. R; Koide T; 
Tibbs C. J; Nouri-Aria K. T; Tokudome S; and Williams R. 1996. 
Usefulness  and  limitation  of  phylogenetic analysis  for  hepatitis  C  virus  
core  region: Application  to  isolates  from  Egyptian  and Yemeni  patients. 
Arch Virol; 141(6): 1101-1113.  
Al-Kubaisy W. A. 1998. Epidemiologic and genotypic distribution of 
hepatitis C in Iraqi pregnant women. Ph.D  thesis.  
Somi M. H; Keivani H; Ardalan M. R; Farhang S; and Pouri A. A. 2008. 
Hepatitis C virus Genotypes in Patients with End-Stage Renal Disease in East 
Azerbaijan Iran. Saudi J Kidney Dis Transpl; 19(3): 461-465   
Esteban J. I; Jordigomez J; Martell M. M; Cabot B; Quer J; Camps J; 
Gonzalez A; Otero T; Moya A; Esteban R; and Guardia J. 1996. 
Transmission of hepatitis c virus by a cardiac surgeon. N Engl J Med; 
334(9): 555-560. 
Cicciarello S; Borgia G; Crowell J; Ciampi R; Cerini R; Orlando R; 
Mainolfi M; Reynaud L; Milano M; and Piazza M. 1997. Prevalence of 
hepatitis C virus genotypes in southern Italy. European Journal of 
Epidemiology; 13(1): 49–54. 
Lee Y. S; Yoon S. K; Chung E. S; Bae S. H; Choi J. Y; Han J. Y; Chung K. 
W; Sun H. S; Kim B. S; and Kim B. K. 2001. The Relationship of 
Histologic Activity to Serum ALT HCV genotype and HCV RNA titers in 
Chronic Hepatitis C. J Korean Med Sci; 16(5): 585-591. 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
388 
Mukaide M; Tanaka Y; Kakuda H; Fujiwara K; Kurbanov F; Orito E; 
Yoshioka K; Fujise K; Harada S; Kozaki T; Takemura K; Hikiji K; and 
Mizokami M. 2005. New combination test for hepatitis C virus genotype 
and viral load determination using Amplicor GT HCV MONITOR test v2.0. 
World J Gastroenterol; 11(4): 469-475. 
Simpore J; Ilboudo D; Samandoulougou A; Guardo P; Castronovo P; and 
Musumeci S. 2004. HCV and HIV Co-Infection in Pregnant Women 
Attending St. Camille Medical Centre in Ouagadougou (Burkina Faso). 
Journal of Medical Virology; 9999: 1–5. 
Sosa-Jurado F; Santos-Lopez G; Guzman-Flores B; Ruiz-Conde J. I; 
Melendez-Mena D; Vargas-Maldonado M. T; Martinez-Laguna Y; 
Contreras-Mioni L; Vallejo-Ruiz V. and Reyes-Leyva J. 2010. Hepatitis C 
virus infection in blood donors from the state of Puebla Mexico. Virology 
Journal; 7:1-16. 
Matar G. M; Sharara H. M; Abdelnour G. E; and Abdelnour A. M. 1996. 
Genotyping of hepatitis C virus isolates from Lebanese hemodialysis 
patients by reverse transcription-PCR and restriction length polymorphism 
analysis of 5’noncoding region. J. Clin. Microbiol; 34(10): 2623- 2624.  
Stuyver L; Wyseur A; van Arnhem W; Lunel F;  Laurent-Puig P; Pawlotsky  
J;  Kleter B; Bassit L; Nkengasong J; van Doorn L; and  Maertens G. 1995. 
Hepatitis C virus genotyping by means of 5'-UR/core line probe assays and 
molecular analysis of untypeable samples. Virus Research; 38(2-3): 137-157. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
